| human | Q5 |
| P2671 | Google Knowledge Graph ID | /g/11f0yxqdzg |
| /g/11ptvnyzvq | ||
| P6634 | LinkedIn personal profile ID | emiel-rutgers-81856512 |
| P7449 | NARCIS researcher ID | PRS1277433 |
| P496 | ORCID iD | 0000-0002-4244-0106 |
| P3368 | Prabook ID | 192779 |
| P166 | award received | Knight of the Order of the Netherlands Lion | Q1818405 |
| P27 | country of citizenship | Kingdom of the Netherlands | Q29999 |
| P734 | family name | Rutgers | Q27518536 |
| Rutgers | Q27518536 | ||
| Rutgers | Q27518536 | ||
| P735 | given name | Emiel | Q17623296 |
| Emiel | Q17623296 | ||
| P106 | occupation | researcher | Q1650915 |
| oncologist | Q16062369 | ||
| P21 | sex or gender | male | Q6581097 |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q34538363 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer |
| Q46152182 | 70-Gene Signature in Early-Stage Breast Cancer |
| Q34658939 | A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q34325583 | A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study |
| Q46191116 | Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy |
| Q33730822 | Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer |
| Q37990824 | Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping |
| Q38023589 | Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. |
| Q81919449 | Are short-term or long-term recurrence rates more important in breast cancer screening? |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q34777432 | Association between genomic recurrence risk and well-being among breast cancer patients |
| Q119213340 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival |
| Q43096833 | Authors' reply to Rayter |
| Q80547969 | Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration |
| Q33747361 | BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study |
| Q50457208 | Breast cancer patients with extra-axillary sentinel nodes only may be spared axillary lymph node dissection. |
| Q50961020 | Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. |
| Q34432389 | Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial |
| Q53340654 | Breast tomosynthesis in clinical practice: initial results. |
| Q46292874 | Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial |
| Q35006280 | Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. |
| Q40828056 | Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors |
| Q90672779 | Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer |
| Q34120676 | Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. |
| Q46502892 | Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer |
| Q82796808 | Chylous fistula after internal mammary chain sentinel node biopsy |
| Q28267891 | Clinical application of the 70-gene profile: the MINDACT trial |
| Q24806527 | Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group |
| Q88446209 | Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study |
| Q47838863 | Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy |
| Q119213355 | Combined skin-sparing mastectomy and immediate implant-based breast reconstruction: Outcome following mantle field irradiation versus outcome following whole-breast irradiation |
| Q119213358 | Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer |
| Q45360546 | Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome |
| Q80594029 | Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up |
| Q97905185 | Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial |
| Q54940119 | Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study. |
| Q98469969 | Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial |
| Q98166987 | Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk |
| Q51222361 | Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. |
| Q38640784 | Current approach of the axilla in patients with early-stage breast cancer |
| Q57116621 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 |
| Q88588452 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 |
| Q42933789 | Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer |
| Q51534303 | Diagnosis of breast cancer using diffuse optical spectroscopy from 500 to 1600 nm: comparison of classification methods. |
| Q33239926 | Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition |
| Q51187701 | Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. |
| Q44473107 | Diffuse reflectance spectroscopy: towards clinical application in breast cancer |
| Q36610188 | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be t |
| Q44581836 | Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk |
| Q36624054 | Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. |
| Q33205307 | Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition |
| Q82854650 | Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study |
| Q61970226 | Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women |
| Q47593437 | European Breast Cancer Conference manifesto on breast centres/units |
| Q60487429 | European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer |
| Q38574130 | Exploring the black box of a decision aid: what information do patients select from an interactive Cd-Rom on treatment options in breast cancer? |
| Q51207597 | Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study. |
| Q33247548 | Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer |
| Q33847261 | Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients |
| Q41472421 | First results of the preoperative accelerated partial breast irradiation (PAPBI) trial |
| Q92975848 | Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial |
| Q35728677 | Follow-up care in breast cancer |
| Q37625239 | Gene expression profiling: decoding breast cancer. |
| Q36613514 | Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q34433731 | Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q51444825 | Immediate breast reconstruction with a myocutaneous latissimus dorsi flap and implant following skin-sparing salvage mastectomy after irradiation as part of breast-conserving therapy. |
| Q38677974 | Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers |
| Q37926544 | Impact of mammographic screening on the detection of good and poor prognosis breast cancers |
| Q37594381 | Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial |
| Q59567641 | Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer |
| Q51053686 | Independent prognostic value of screen detection in invasive breast cancer. |
| Q28249470 | Individualization of therapy using Mammaprint: from development to the MINDACT Trial |
| Q86056348 | Intraoperative assessment of axillary lymph nodes in patients with breast cancer |
| Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
| Q38264840 | Is axillary lymph node clearance required in node-positive breast cancer? |
| Q91989205 | Is prophylactic mastectomy justified in women without BRCA mutation? |
| Q48048490 | Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients |
| Q81098394 | Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer |
| Q40597534 | Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute |
| Q34042621 | Lymph node staging in invasive breast cancer |
| Q53321748 | Lymphatic drainage patterns from the treated breast. |
| Q54594741 | Lymphatic drainage patterns in breast cancer patients who previously underwent mantle field radiation. |
| Q33194158 | MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC) |
| Q92915467 | MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial |
| Q46124296 | MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy |
| Q37583102 | Mammographic screening detects low-risk tumor biology breast cancers |
| Q84524367 | Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer |
| Q119213349 | Maximising the preservation of previously irradiated native mammary skin by skin-banking of the autologous flap: Outcome after 33 skin-sparing or nipple-sparing salvage mastectomies |
| Q43186231 | Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature |
| Q53377954 | Micrometastases or isolated tumor cells and the outcome of breast cancer. |
| Q59567719 | Molecular Forecasting of Breast Cancer: Time to Move Forward With Clinical Testing |
| Q51679573 | On the feasibility of MRI-guided navigation to demarcate breast cancer for breast-conserving surgery. |
| Q33651520 | Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms |
| Q39382712 | Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. |
| Q97685663 | Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials |
| Q51325823 | PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. |
| Q41096854 | Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. |
| Q79393410 | Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q90132738 | Prognosis of acute coronary syndromes after radiotherapy for breast cancer |
| Q88570200 | Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients |
| Q45106317 | Prognostic Significance of Tumor-Positive Internal Mammary Sentinel Lymph Nodes in Breast Cancer: A Multicenter Cohort Study. |
| Q81368384 | Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience |
| Q44352161 | Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer |
| Q40423785 | Radio-immunotargeting in colorectal carcinoma |
| Q50553096 | Radioactive seed localization in breast cancer treatment. |
| Q86633307 | Radiotherapy or surgery for the axilla in node-positive breast cancer?--authors' reply |
| Q34919537 | Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial |
| Q44035770 | Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up |
| Q48518470 | Real-time wireless tumor tracking during breast conserving surgery. |
| Q73366646 | Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer |
| Q48571303 | Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. |
| Q49885737 | Reply to letter from Suguatti et al. |
| Q90124638 | Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients |
| Q99610358 | Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study |
| Q33710557 | Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer |
| Q34380273 | Scenario drafting to anticipate future developments in technology assessment |
| Q84918014 | Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study |
| Q36814404 | Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy |
| Q50481106 | Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. |
| Q37079591 | Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases |
| Q33928258 | Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial |
| Q75282622 | Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more? |
| Q81390829 | Sentinel-lymph-node biopsy in breast cancer |
| Q50492580 | Should the Hunt for Internal Mammary Chain Sentinel Nodes Begin? An Evaluation of 150 Breast Cancer Patients |
| Q89830028 | Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial |
| Q36131718 | Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women |
| Q51276495 | Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC). |
| Q35007777 | The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. |
| Q59567512 | The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase |
| Q28242008 | The MINDACT trial: the first prospective clinical validation of a genomic tool |
| Q40926467 | The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands |
| Q50457446 | The hidden sentinel node and SPECT/CT in breast cancer patients. |
| Q50204926 | The hidden sentinel node in breast cancer: Reevaluating the role of SPECT/CT and tracer reinjection. |
| Q36646603 | The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer |
| Q88441068 | The intraoperative assessment of sentinel nodes - Standards and controversies |
| Q37690088 | The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study |
| Q55052653 | The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. |
| Q47809790 | The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma |
| Q46811586 | The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer |
| Q30896495 | Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study |
| Q82056301 | Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy |
| Q34563697 | Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer |
| Q82083040 | Validation of 70-gene prognosis signature in node-negative breast cancer |
| Q85071879 | Variation between hospitals in surgical margins after first breast-conserving surgery in the Netherlands |
| Q57129628 | [Gene expression classifiers in the prognosis of breast cancer] |
| Q84619738 | [How can breast-conserving surgery be improved even more?] |
| Q82393859 | [The long-term prognosis of locally recurrent breast cancer after breast conserving treatment] |
| Q53197851 | [The value of ipsilateral breast tumor recurrence as a quality indicator: hospital variation in the Netherlands]. |
| Emiel Rutgers | wikipedia |
Search more.